3thx

From Proteopedia

(Difference between revisions)
Jump to: navigation, search
Current revision (10:09, 1 March 2024) (edit) (undo)
 
Line 3: Line 3:
<StructureSection load='3thx' size='340' side='right'caption='[[3thx]], [[Resolution|resolution]] 2.70&Aring;' scene=''>
<StructureSection load='3thx' size='340' side='right'caption='[[3thx]], [[Resolution|resolution]] 2.70&Aring;' scene=''>
== Structural highlights ==
== Structural highlights ==
-
<table><tr><td colspan='2'>[[3thx]] is a 4 chain structure with sequence from [https://en.wikipedia.org/wiki/Human Human]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=3THX OCA]. For a <b>guided tour on the structure components</b> use [https://proteopedia.org/fgij/fg.htm?mol=3THX FirstGlance]. <br>
+
<table><tr><td colspan='2'>[[3thx]] is a 4 chain structure with sequence from [https://en.wikipedia.org/wiki/Homo_sapiens Homo sapiens]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=3THX OCA]. For a <b>guided tour on the structure components</b> use [https://proteopedia.org/fgij/fg.htm?mol=3THX FirstGlance]. <br>
-
</td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat" id="ligandDat"><scene name='pdbligand=ADP:ADENOSINE-5-DIPHOSPHATE'>ADP</scene>, <scene name='pdbligand=NA:SODIUM+ION'>NA</scene></td></tr>
+
</td></tr><tr id='method'><td class="sblockLbl"><b>[[Empirical_models|Method:]]</b></td><td class="sblockDat" id="methodDat">X-ray diffraction, [[Resolution|Resolution]] 2.7&#8491;</td></tr>
-
<tr id='related'><td class="sblockLbl"><b>[[Related_structure|Related:]]</b></td><td class="sblockDat"><div style='overflow: auto; max-height: 3em;'>[[3thw|3thw]], [[3thy|3thy]], [[3thz|3thz]]</div></td></tr>
+
<tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat" id="ligandDat"><scene name='pdbligand=ADP:ADENOSINE-5-DIPHOSPHATE'>ADP</scene>, <scene name='pdbligand=NA:SODIUM+ION'>NA</scene></td></tr>
-
<tr id='gene'><td class="sblockLbl"><b>[[Gene|Gene:]]</b></td><td class="sblockDat">MSH2 ([https://www.ncbi.nlm.nih.gov/Taxonomy/Browser/wwwtax.cgi?mode=Info&srchmode=5&id=9606 HUMAN]), DUC1, DUG, MSH3 ([https://www.ncbi.nlm.nih.gov/Taxonomy/Browser/wwwtax.cgi?mode=Info&srchmode=5&id=9606 HUMAN])</td></tr>
+
<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=3thx FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=3thx OCA], [https://pdbe.org/3thx PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=3thx RCSB], [https://www.ebi.ac.uk/pdbsum/3thx PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=3thx ProSAT]</span></td></tr>
<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=3thx FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=3thx OCA], [https://pdbe.org/3thx PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=3thx RCSB], [https://www.ebi.ac.uk/pdbsum/3thx PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=3thx ProSAT]</span></td></tr>
</table>
</table>
== Disease ==
== Disease ==
-
[[https://www.uniprot.org/uniprot/MSH2_HUMAN MSH2_HUMAN]] Defects in MSH2 are the cause of hereditary non-polyposis colorectal cancer type 1 (HNPCC1) [MIM:[https://omim.org/entry/120435 120435]]. Mutations in more than one gene locus can be involved alone or in combination in the production of the HNPCC phenotype (also called Lynch syndrome). Most families with clinically recognized HNPCC have mutations in either MLH1 or MSH2 genes. HNPCC is an autosomal, dominantly inherited disease associated with marked increase in cancer susceptibility. It is characterized by a familial predisposition to early onset colorectal carcinoma (CRC) and extra-colonic cancers of the gastrointestinal, urological and female reproductive tracts. HNPCC is reported to be the most common form of inherited colorectal cancer in the Western world. Cancers in HNPCC originate within benign neoplastic polyps termed adenomas. Clinically, HNPCC is often divided into two subgroups. Type I: hereditary predisposition to colorectal cancer, a young age of onset, and carcinoma observed in the proximal colon. Type II: patients have an increased risk for cancers in certain tissues such as the uterus, ovary, breast, stomach, small intestine, skin, and larynx in addition to the colon. Diagnosis of classical HNPCC is based on the Amsterdam criteria: 3 or more relatives affected by colorectal cancer, one a first degree relative of the other two; 2 or more generation affected; 1 or more colorectal cancers presenting before 50 years of age; exclusion of hereditary polyposis syndromes. The term "suspected HNPCC" or "incomplete HNPCC" can be used to describe families who do not or only partially fulfill the Amsterdam criteria, but in whom a genetic basis for colon cancer is strongly suspected. MSH2 mutations may predispose to hematological malignancies and multiple cafe-au-lait spots.<ref>PMID:8261515</ref> <ref>PMID:9889267</ref> <ref>PMID:7874129</ref> <ref>PMID:8872463</ref> <ref>PMID:8700523</ref> <ref>PMID:9311737</ref> <ref>PMID:9240418</ref> <ref>PMID:9419403</ref> <ref>PMID:9048925</ref> <ref>PMID:9298827</ref> <ref>PMID:9718327</ref> <ref>PMID:9559627</ref> <ref>PMID:10375096</ref> <ref>PMID:10573010</ref> <ref>PMID:10386556</ref> <ref>PMID:10528862</ref> <ref>PMID:10777691</ref> <ref>PMID:10612836</ref> <ref>PMID:10829038</ref> <ref>PMID:12132870</ref> <ref>PMID:11726306</ref> <ref>PMID:12373605</ref> <ref>PMID:11920458</ref> <ref>PMID:12124176</ref> <ref>PMID:12112654</ref> <ref>PMID:12200596</ref> <ref>PMID:11870161</ref> <ref>PMID:12362047</ref> <ref>PMID:12658575</ref> <ref>PMID:12655564</ref> <ref>PMID:12655568</ref> <ref>PMID:14635101</ref> <ref>PMID:15046096</ref> <ref>PMID:15300854</ref> <ref>PMID:15365995</ref> <ref>PMID:15613555</ref> <ref>PMID:15342696</ref> <ref>PMID:15896463</ref> <ref>PMID:15996210</ref> <ref>PMID:15870828</ref> <ref>PMID:15991316</ref> <ref>PMID:16451135</ref> <ref>PMID:17101317</ref> <ref>PMID:17128465</ref> <ref>PMID:18625694</ref> <ref>PMID:18951462</ref> <ref>PMID:18561205</ref> <ref>PMID:18781619</ref> <ref>PMID:18822302</ref> <ref>PMID:22102614</ref> <ref>PMID:22371642</ref> Defects in MSH2 are a cause of Muir-Torre syndrome (MRTES) [MIM:[https://omim.org/entry/158320 158320]]. Rare autosomal dominant disorder characterized by sebaceous neoplasms and visceral malignancy.<ref>PMID:7713503</ref> Defects in MSH2 are a cause of susceptibility to endometrial cancer (ENDMC) [MIM:[https://omim.org/entry/608089 608089]].
+
[https://www.uniprot.org/uniprot/MSH2_HUMAN MSH2_HUMAN] Defects in MSH2 are the cause of hereditary non-polyposis colorectal cancer type 1 (HNPCC1) [MIM:[https://omim.org/entry/120435 120435]. Mutations in more than one gene locus can be involved alone or in combination in the production of the HNPCC phenotype (also called Lynch syndrome). Most families with clinically recognized HNPCC have mutations in either MLH1 or MSH2 genes. HNPCC is an autosomal, dominantly inherited disease associated with marked increase in cancer susceptibility. It is characterized by a familial predisposition to early onset colorectal carcinoma (CRC) and extra-colonic cancers of the gastrointestinal, urological and female reproductive tracts. HNPCC is reported to be the most common form of inherited colorectal cancer in the Western world. Cancers in HNPCC originate within benign neoplastic polyps termed adenomas. Clinically, HNPCC is often divided into two subgroups. Type I: hereditary predisposition to colorectal cancer, a young age of onset, and carcinoma observed in the proximal colon. Type II: patients have an increased risk for cancers in certain tissues such as the uterus, ovary, breast, stomach, small intestine, skin, and larynx in addition to the colon. Diagnosis of classical HNPCC is based on the Amsterdam criteria: 3 or more relatives affected by colorectal cancer, one a first degree relative of the other two; 2 or more generation affected; 1 or more colorectal cancers presenting before 50 years of age; exclusion of hereditary polyposis syndromes. The term "suspected HNPCC" or "incomplete HNPCC" can be used to describe families who do not or only partially fulfill the Amsterdam criteria, but in whom a genetic basis for colon cancer is strongly suspected. MSH2 mutations may predispose to hematological malignancies and multiple cafe-au-lait spots.<ref>PMID:8261515</ref> <ref>PMID:9889267</ref> <ref>PMID:7874129</ref> <ref>PMID:8872463</ref> <ref>PMID:8700523</ref> <ref>PMID:9311737</ref> <ref>PMID:9240418</ref> <ref>PMID:9419403</ref> <ref>PMID:9048925</ref> <ref>PMID:9298827</ref> <ref>PMID:9718327</ref> <ref>PMID:9559627</ref> <ref>PMID:10375096</ref> <ref>PMID:10573010</ref> <ref>PMID:10386556</ref> <ref>PMID:10528862</ref> <ref>PMID:10777691</ref> <ref>PMID:10612836</ref> <ref>PMID:10829038</ref> <ref>PMID:12132870</ref> <ref>PMID:11726306</ref> <ref>PMID:12373605</ref> <ref>PMID:11920458</ref> <ref>PMID:12124176</ref> <ref>PMID:12112654</ref> <ref>PMID:12200596</ref> <ref>PMID:11870161</ref> <ref>PMID:12362047</ref> <ref>PMID:12658575</ref> <ref>PMID:12655564</ref> <ref>PMID:12655568</ref> <ref>PMID:14635101</ref> <ref>PMID:15046096</ref> <ref>PMID:15300854</ref> <ref>PMID:15365995</ref> <ref>PMID:15613555</ref> <ref>PMID:15342696</ref> <ref>PMID:15896463</ref> <ref>PMID:15996210</ref> <ref>PMID:15870828</ref> <ref>PMID:15991316</ref> <ref>PMID:16451135</ref> <ref>PMID:17101317</ref> <ref>PMID:17128465</ref> <ref>PMID:18625694</ref> <ref>PMID:18951462</ref> <ref>PMID:18561205</ref> <ref>PMID:18781619</ref> <ref>PMID:18822302</ref> <ref>PMID:22102614</ref> <ref>PMID:22371642</ref> Defects in MSH2 are a cause of Muir-Torre syndrome (MRTES) [MIM:[https://omim.org/entry/158320 158320]. Rare autosomal dominant disorder characterized by sebaceous neoplasms and visceral malignancy.<ref>PMID:7713503</ref> Defects in MSH2 are a cause of susceptibility to endometrial cancer (ENDMC) [MIM:[https://omim.org/entry/608089 608089].
== Function ==
== Function ==
-
[[https://www.uniprot.org/uniprot/MSH2_HUMAN MSH2_HUMAN]] Component of the post-replicative DNA mismatch repair system (MMR). Forms two different heterodimers: MutS alpha (MSH2-MSH6 heterodimer) and MutS beta (MSH2-MSH3 heterodimer) which binds to DNA mismatches thereby initiating DNA repair. When bound, heterodimers bend the DNA helix and shields approximately 20 base pairs. MutS alpha recognizes single base mismatches and dinucleotide insertion-deletion loops (IDL) in the DNA. MutS beta recognizes larger insertion-deletion loops up to 13 nucleotides long. After mismatch binding, MutS alpha or beta forms a ternary complex with the MutL alpha heterodimer, which is thought to be responsible for directing the downstream MMR events, including strand discrimination, excision, and resynthesis. ATP binding and hydrolysis play a pivotal role in mismatch repair functions. The ATPase activity associated with MutS alpha regulates binding similar to a molecular switch: mismatched DNA provokes ADP-->ATP exchange, resulting in a discernible conformational transition that converts MutS alpha into a sliding clamp capable of hydrolysis-independent diffusion along the DNA backbone. This transition is crucial for mismatch repair. MutS alpha may also play a role in DNA homologous recombination repair. In melanocytes may modulate both UV-B-induced cell cycle regulation and apoptosis.<ref>PMID:9822680</ref> <ref>PMID:9822679</ref> <ref>PMID:9564049</ref> <ref>PMID:10078208</ref> <ref>PMID:10660545</ref> <ref>PMID:15064730</ref> <ref>PMID:17611581</ref>
+
[https://www.uniprot.org/uniprot/MSH2_HUMAN MSH2_HUMAN] Component of the post-replicative DNA mismatch repair system (MMR). Forms two different heterodimers: MutS alpha (MSH2-MSH6 heterodimer) and MutS beta (MSH2-MSH3 heterodimer) which binds to DNA mismatches thereby initiating DNA repair. When bound, heterodimers bend the DNA helix and shields approximately 20 base pairs. MutS alpha recognizes single base mismatches and dinucleotide insertion-deletion loops (IDL) in the DNA. MutS beta recognizes larger insertion-deletion loops up to 13 nucleotides long. After mismatch binding, MutS alpha or beta forms a ternary complex with the MutL alpha heterodimer, which is thought to be responsible for directing the downstream MMR events, including strand discrimination, excision, and resynthesis. ATP binding and hydrolysis play a pivotal role in mismatch repair functions. The ATPase activity associated with MutS alpha regulates binding similar to a molecular switch: mismatched DNA provokes ADP-->ATP exchange, resulting in a discernible conformational transition that converts MutS alpha into a sliding clamp capable of hydrolysis-independent diffusion along the DNA backbone. This transition is crucial for mismatch repair. MutS alpha may also play a role in DNA homologous recombination repair. In melanocytes may modulate both UV-B-induced cell cycle regulation and apoptosis.<ref>PMID:9822680</ref> <ref>PMID:9822679</ref> <ref>PMID:9564049</ref> <ref>PMID:10078208</ref> <ref>PMID:10660545</ref> <ref>PMID:15064730</ref> <ref>PMID:17611581</ref>
-
<div style="background-color:#fffaf0;">
+
-
== Publication Abstract from PubMed ==
+
-
DNA mismatch repair corrects replication errors, thus reducing mutation rates and microsatellite instability. Genetic defects in this pathway cause Lynch syndrome and various cancers in humans. Binding of a mispaired or unpaired base by bacterial MutS and eukaryotic MutSalpha is well characterized. We report here crystal structures of human MutSbeta in complex with DNA containing insertion-deletion loops (IDL) of two, three, four or six unpaired nucleotides. In contrast to eukaryotic MutSalpha and bacterial MutS, which bind the base of a mismatched nucleotide, MutSbeta binds three phosphates in an IDL. DNA is severely bent at the IDL; unpaired bases are flipped out into the major groove and partially exposed to solvent. A normal downstream base pair can become unpaired; a single unpaired base can thereby be converted to an IDL of two nucleotides and recognized by MutSbeta. The C-terminal dimerization domains form an integral part of the MutS structure and coordinate asymmetrical ATP hydrolysis by Msh2 and Msh3 with mismatch binding to signal for repair.
+
-
 
+
-
Mechanism of mismatch recognition revealed by human MutSbeta bound to unpaired DNA loops.,Gupta S, Gellert M, Yang W Nat Struct Mol Biol. 2011 Dec 18;19(1):72-8. doi: 10.1038/nsmb.2175. PMID:22179786<ref>PMID:22179786</ref>
+
-
 
+
-
From MEDLINE&reg;/PubMed&reg;, a database of the U.S. National Library of Medicine.<br>
+
-
</div>
+
-
<div class="pdbe-citations 3thx" style="background-color:#fffaf0;"></div>
+
==See Also==
==See Also==
Line 29: Line 19:
__TOC__
__TOC__
</StructureSection>
</StructureSection>
-
[[Category: Human]]
+
[[Category: Homo sapiens]]
[[Category: Large Structures]]
[[Category: Large Structures]]
-
[[Category: Yang, W]]
+
[[Category: Yang W]]
-
[[Category: Abc family atpase]]
+
-
[[Category: Dna binding protein-dna complex]]
+
-
[[Category: Mismatch recognition]]
+
-
[[Category: Mismatched unpaired idl dna]]
+

Current revision

Human MutSbeta complexed with an IDL of 3 bases (Loop3) and ADP

PDB ID 3thx

Drag the structure with the mouse to rotate

Proteopedia Page Contributors and Editors (what is this?)

OCA

Retrieved from "http://52.214.119.220/wiki/index.php/3thx"
Personal tools